Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.56 |
| ▸ | NPY1R | P25929 | 7/20 | 0.56 |
| ▸ | NPY2R | P49146 | 5/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.47 |
| ▸ | BACE1 | P56817 | 1/20 | 0.47 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29839246 | 0.95 | NPY4R (0.59) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL30496421 | 0.92 | NPY4R (0.59) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL30918767 | 0.92 | NPY4R (0.57) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL29649734 | 0.90 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL30331385 | 0.90 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL29649760 | 0.90 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL29559026 | 0.90 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL29839266 | 0.89 | NPY4R (0.58) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL30918766 | 0.89 | NPY4R (0.61) | NPY4RNPY1RNPY2RNPY5ROPRD1 | |
| SCHEMBL31233596 | 0.89 | NPY4R (0.60) | NPY4RNPY1RNPY2RNPY5RBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220257698-A1 | ANGIOTENSIN TYPE 2 (AT2) RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF CANCER | LANTHIOPEP B.V. (NL) | 2022-08-18 | — | — | US | disclosed |
| EP-4007592-A1 | ANGIOTENSIN TYPE 2 (AT2) RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF CANCER | LanthioPep B.V. (NL) | 2022-06-08 | — | — | EP | disclosed |
| CN-114514032-A | Angiotensin type 2 (AT2) receptor agonists for the treatment of cancer | 兰提欧派普有限公司 | 2022-05-17 | — | — | CN | disclosed |